Q2 25 EPS
$1.26
BEAT +0.80%
Est. $1.25
Q2 25 Revenue
$11.14B
BEAT +1.08%
Est. $11.02B
vs S&P Since Q2 25
-40.3%
TRAILING MARKET
ABT -25.5% vs S&P +14.7%
Market Reaction
Did ABT Beat Earnings? Q2 2025 Results
Abbott Laboratories posted a clean beat across both top and bottom lines in the second quarter of 2025, with adjusted diluted EPS of $1.26 edging past the $1.25 consensus estimate and revenue of $11.14 billion topping expectations by 1.08% on 7.4% ye… Read more Abbott Laboratories posted a clean beat across both top and bottom lines in the second quarter of 2025, with adjusted diluted EPS of $1.26 edging past the $1.25 consensus estimate and revenue of $11.14 billion topping expectations by 1.08% on 7.4% year-over-year growth. The primary engine behind the quarter was the Medical Devices segment, which expanded 13.4% on a reported basis, anchored by Diabetes Care, where continuous glucose monitor sales reached $1.90 billion, up 21.4% year-over-year, largely driven by FreeStyle Libre. Margin discipline was equally notable, with adjusted gross margin rising 100 basis points to 57.0% and adjusted operating margin expanding 100 basis points to 22.9%, reflecting operating leverage across the portfolio. Despite the solid print, shares fell sharply following the release. Looking ahead, Abbott raised its full-year 2025 adjusted diluted EPS guidance to $5.10 to $5.20, implying double-digit growth at the midpoint, while projecting organic sales growth of 7.5% to 8.0% excluding COVID-19 testing.
Key Takeaways
- • Double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology within Medical Devices
- • Continuous glucose monitor sales of $1.9 billion, up 21.4% reported
- • Strong performance of FreeStyle Libre, Navitor, TriClip, and AVEIR products
- • Adult Nutrition organic growth of 6.6% led by Ensure and Glucerna
- • Established Pharmaceuticals Key Emerging Markets organic growth of 8.7% with double-digit growth in several countries across Asia, Latin America, and the Middle East
- • 100 basis point expansion in both adjusted gross margin and adjusted operating margin
ABT YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
ABT Revenue by Segment
With YoY comparisons, source: SEC Filings
ABT Revenue by Geography
With YoY comparisons, source: SEC Filings
“Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline. We see this momentum carrying into 2026.”
— Robert B. Ford, Q2 2025 Earnings Press Release
ABT Earnings Trends
ABT vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABT EPS Trend
Earnings per share: estimate vs actual
ABT Revenue Trend
Quarterly revenue: estimate vs actual
ABT Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $1.15 | — | $11.16B | +1.51% |
| Q4 25 BEAT FY | $1.49 | $1.50 | +0.67% | $11.46B | -2.94% |
| FY Full Year | $5.17 | $5.15 | -0.42% | $44.33B | -0.78% |
| Q3 25 BEAT | $1.30 | $1.30 | +0.05% | $11.37B | -0.21% |
| Q2 25 BEAT | $1.25 | $1.26 | +0.80% | $11.14B | +1.08% |
| Q1 25 BEAT | $1.07 | $1.09 | +1.75% | $10.36B | -0.57% |